Our results are similar to the results of Cortelezzi et al. in terms of Overall Response Rate (ORR) (47 vs 53%), median overall survival (29 vs 30 months) and fatal events (52 vs 55%, with median follow-up of 33 and 25 months, respectively). Regarding safety and tolerability, in both studies alemtuzumab therapy was well tolerated and most of the adverse events were transient, although we observed more cases of grade III-IV anemia (21 vs 3.3%), grade III-IV neutropenia (52 vs 36%), low grade fever (36 vs 14%) and CMV reactivation (47 vs 25%). A possible explanation for the last discrepancy could be the different threshold values and application of the CMV-DNA assay to define CMV reactivation. 5
However, it is important to note that in both series none of the patients developed clinically relevant CMV disease.
In conclusion, we confirm the data of Cortelezzi et al. regarding the efficacy and tolerability of low-dose alemtuzumab, although some noteworthy differences emerged between the two studies. Their data showed an increased complete response rate (27 vs 16%) and a longer median time to alternative treatment (9 vs 7 months), but also a higher rate of infectious complications during and after treatment (0.6 vs 0.0 episodes per patient) and a smaller proportion of patients who completed the planned treatment (38/49 vs 16/19). These differences are probably because of the higher cumulative dose of alemtuzumab in their study (480 vs 300 mg), which translated into somewhat greater efficacy but also a greater incidence of infectious complications, among which one third were severe or life threatening. Thus, we agree with Cortelezzi et al. that lowdose alemtuzumab is an effective therapeutic option in refractory chronic lymphocytic leukemia, especially in the setting of elderly and poor prognosis patients, but believe that additional studies are required to define the optimal duration of treatment. The t(8;21) (q22;q22) is a common translocation in acute myeloid leukemia (AML). In this translocation the AML1 (RUNX1) gene coding for a DNA-binding domain, is fused to most of the ETO (RUNX1T1) gene, which encodes four nervy homology regions (NHRs) that function as repressors of transcription. The resulting fusion gene AML1-ETO (RUNX1-RUNX1T1), which gives rise to a major transcript coding for a product of 752 amino acids (aa), is alone insufficient to cause leukemia in animal models; suggesting additional genetic aberrations are required to achieve full leukemic potential. However, studies have shown alternative transcripts of AML1-ETO to be co-expressed alongside the full-length transcript. 1 These transcripts often occur as a result of alternative exon usage and importantly appear to have a role in the leukemogenic capabilities of this translocation. For example, the utilization of the alternative ETO exon 9a results in a truncated AML1-ETO product of 552 aa lacking the NHR3 and NHR4 domains and whose expression in mouse models leads to the rapid development of leukemia. 2 Our aim was to analyze further alternative transcripts of AML1-ETO. Our discoveries have revealed further exons and alternative transcripts of AML1-ETO whose clonogenic potential has been assessed.
Informed written consent was obtained before storing of patient samples. The AML1-ETO exon 9a transcript was amplified by reverse transcriptase PCR (RT-PCR) using RNA extracted from both Kasumi cell lines and 10 primary t(8;21) samples ( Table 1 ). The PCR products were cloned and sequenced. In addition to the 9a transcript, a further unique transcript containing an unidentified sequence inserted between ETO exons 5 and 6 but lacking ETO exon 3 was noted. A blat search (http://genome.ucsc.edu/cgi-bin/hgBlat) confirmed the unidentified sequence as part of the ETO gene and subsequently referred to as ETO exon 6a ( Figure 1a ). Further RT-PCR, using primers for exon 6a, followed by cloning and sequencing confirmed the presence of an additional exon 6a-containing transcript, which retained both exons 3 and 6a ( Figure 1a and Supplementary Figure 1) .
ETO exon 6a has 137 base pairs and is located at chromosome 8:93075890-93076027 on the human genome (version hg 18 March 2006). It is flanked by base pairs AG and GT, which are splice donor and acceptor motifs in eukaryotic genes. The full sequence of exon 6a is as follows: 5 0 -ATGA ATAAACTGAGGTCCAGAGAGGTTAAGTGACTTGACCAAGG TCACACAGCTAGTCATGGAAGAGCCAGGACTAGATCTCAG GTCTCTTGATTCCCAGTCCAGTGCTCTTTCCACTACACCACA ATGCCAGTAAG-3 0 . The incorporation of exon 6a was found in at least two AML1-ETO transcripts potentially giving rise to two truncated forms of the AML1-ETO protein. In the shorter transcript (AML1-ETO 6a-sh), ETO exon 3 is spliced out resulting in the introduction of a premature stop codon at the end of exon 2 and is predicted to give rise to a truncated AML1-ETO protein of 223aa, lacking all four NHR domains of ETO. In the longer transcript (AML1-ETO 6a), both exon 3 and exon 6a from the primary transcript are retained, resulting in the introduction of a premature stop codon at the end of ETO exon 5. The protein generated by this transcript is predicted to be 395aa, retaining the NHR1 domain but lacking the NHR 2, 3 and 4 domains. AML1-ETO transcripts predicted to yield identical 395aa sequences have been described earlier, although in these reports the termination of the transcripts were as a result of the introduction of other intronic sequences and not the novel exon described here. 3, 4 We confirmed the presence of the exon 6a-containing transcripts in all 10 t(8;21) patient samples by real-time PCR (RQ-PCR). There are large differences in the quantities of each isoform between patients ( Figure 1b) ; however, the small sample size precludes drawing any firm conclusions regarding levels of transcripts and patient outcome. Comparisons of transcript levels within each patient shows that 6a transcripts are generally but not always less abundant than the 9a transcript and consistently 5-to 10-fold less abundant than the full-length AML1-ETO transcript (supplementary Figure 2) .
To analyze the role of the NHR1 domain in AML1-ETOinduced leukemogenesis the AML1-ETO 6a transcript was used for further functional assessment. Initially, pMSCV AML1-ETO 6a-iresGFP (pMiG-A-E6a) and pMSCV AML1-ETO-ires hCD2 (pMihC-A-E) vectors were constructed and their protein expression in packaging cell lines was confirmed by western blotting (Figures 1c and d, respectively) . To examine the effect of the truncated protein, murine hemopoietic stem cells were infected with AML1-ETO vectors and subjected to methylcellulose re-plating assays as described earlier. 5 Transduction with the AML1-ETO 6a retrovirus appears to have minimal affect on cell number (Figure 2a ) or colony morphology in first round methylcellulose plates. Similarly, cells transduced with this retrovirus did not re-plate beyond the third round, unlike the full-length and 9a vectors, indicating a lack of immortalization capacity (Figure 2b) .
We next performed dual transduction experiments, with full-length and 6a AML1-ETO viruses, to more closely mimic in vivo activity (Supplementary Figure 3) . In contrast to the above observations, the expression of the 6a AML1-ETO vector appears to suppress AML1-ETO-dependent re-plating capacity. (Figure 2c) .
We have described a novel in vivo AML1-ETO transcript, containing the NHR1 domain and lacking the other NHR domains, and have shown that it lacks clonogenic potential in AML1-ETO-induced leukemogenesis. As the 9a transcript containing the NHRs 1 and 2 domains can induce leukemia unlike the 6a transcript, which lacks the NHR2 domain, it can In addition to the major full-length AML1-ETO product containing for all four NHRs, truncated proteins lacking NHRs as result of alternative exon usage of 11a, 9a and 6a, respectively are summarized. Utilization of the 6a exon can result in at least two transcripts with a short form coding for a protein lacking all four NHRs (6a sh).
Letters to the Editor be deduced that the NHR2 domain of ETO is essential in the leukemogenic capacity of the AML1-ETO fusion protein.
The homo-oligomerization function imparted by the NHR2 domain appears to be the key mechanism for leukemogenesis in the pathogenesis of AML with t(8;21). 6 By introducing specific mutations into the regions coding for the NHR1 and NHR2 domains of AML1-ETO transcripts, three recent reports have confirmed a limited role of the NHR1 domain. [6] [7] [8] Although our results are in keeping with these findings, we further show that the novel 6a-containing transcript may influence the clonogenic potential of the full-length transcript. This observation highlights another potential failsafe mechanism by which cells may be able to regulate uncontrolled leukemic growth.
In addition, the AML1-ETO 6a-sh transcript, although giving rise to a protein lacking all four NHR domains, may still have a role in leukemogenesis through a dominant-negative effect, competing with native AML1 or full-length AML1-ETO for DNAbinding sites.
These observations provide further insights into the role of alternative transcripts in leukemogenesis. As a result of alternative exon usage, a whole range of alternative transcripts are produced concurrently in t(8;21) leukemic samples. These transcripts encode for proteins that lack the various NHR domains (Figure 2d ). The interactions of these proteins with each other appear to be complex affecting the leukemic potential of the major full-length AML1-ETO product.
In summary, we have detected a novel exon of ETO, which is used to form further alternative transcripts of AML1-ETO. We confirm that a transcript giving rise to a protein of 395aa and lacking NHRs 2, 3 and 4 domains is not clonogenic on its own but appears to modulate clonogenic potential of the full-length AML1-ETO transcript.
